Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Yashinsky

Internal Medicine Southfield, MI Medical Doctor

NPI 1649271115 CMS profile 301816

29355 Northwestern Hwy, Ste. 120, Southfield, MI 48034

Open in the dashboard

General payments

$10,866

534 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Yashinsky of Southfield, MI is reported in the CMS Open Payments database as having received $10,866 across 534 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,549 116
2024 General $2,434 126
2023 General $2,074 113
2022 General $1,270 60
2021 General $317 15
2020 General $434 7
2019 General $1,789 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Yashinsky
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gary Yashinsky were reported at $2,549. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gary Yashinsky Internal Medicine median Middle half National median
2019 $1,789 $159 $48–$570 $163
2020 $434 $119 $33–$402 $114
2021 $317 $135 $37–$521 $132
2022 $1,270 $141 $42–$496 $149
2023 $2,074 $149 $45–$519 $160
2024 $2,434 $154 $47–$537 $164
2025 $2,549 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,612 169 payments
  2. AstraZeneca Pharmaceuticals LP $1,701 44 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $722 23 payments
  4. Xeris Pharmaceuticals, Inc. $615 27 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $508 28 payments
  6. Lilly USA, LLC $409 16 payments
  7. Janssen Pharmaceuticals, Inc $374 19 payments
  8. AbbVie, Inc. $360 20 payments
  9. Amgen Inc. $354 23 payments
  10. Pfizer Inc. $344 22 payments
  11. Other $2,867 143 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,717 530 payments
  2. Education $79 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $1,698 106 payments
  2. Ozempic $1,630 115 payments
  3. FARXIGA $1,011 21 payments
  4. Kerendia $622 22 payments
  5. GVOKE HYPOPEN $502 22 payments
  6. Wegovy $423 30 payments
  7. XARELTO $368 18 payments
  8. AIRSUPRA $333 7 payments
  9. Saxenda $332 24 payments
  10. MOUNJARO $288 6 payments
  11. Other $6,561 401 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 210 drugs

Part D claims

17,948

Median for Internal Medicine: 777

Drug cost

$1,758,996

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 201 $423,560
Farxiga Dapagliflozin Propanediol Brand 158 $158,383
Eliquis Apixaban Brand 192 $157,758
Jardiance Empagliflozin Brand 93 $93,417
Trulicity Dulaglutide Brand 68 $85,741
Mounjaro Tirzepatide Brand 69 $75,972
Januvia Sitagliptin Phosphate Brand 60 $69,599
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 87 $61,552
Xarelto Rivaroxaban Brand 45 $60,277
Rybelsus Semaglutide Brand 22 $32,162

The 10 drugs with the highest cost, of 210 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$53,386

Medicare's payments for the services billed

Medicare patients

388

Average age 74

Services billed

1,851

208 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 34%
Ischemic heart disease 28%
Cancer 19%
Chronic kidney disease 16%
Depression 15%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $217
$217 22 —
Ozempic
  • Novo Nordisk Inc $217
$217 201 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $199
$199 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $141
$141 158 —
MOUNJARO
  • Lilly USA, LLC $125
$125 69 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

534 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record